Eyes on BMS, Pfizer, & Amgen
Eye's on the Amgen data releases for gMG & Atopic Dermatitis, the BMS approval of Cobenfy for schizophrenia, and Pfizer's Oxbryta recall...
Check-out What Intel Caught our Eye
Eyes on BMS, Pfizer, & Amgen
Eyes On the Competition
Eyes on Oncology, Anti-Virals, and Consumer Products
Eyes on ASCO 2024
Our Comments & Links on Top 4 Biggest Drugs in 2023
1Q24 BioPharma Deals & Raises
Eyes on Corporate Restructuring
Eyes on Current Events - Deals, Approvals & Operations
Eyes on Genetic Medicines & Pipelines
Eyes on Clinical Trial Data, Supply Upgrades, and Patent Litigation
Opioids, SPACs, Top 10 Lists, and more Results
R&D Trends, ASCO-GU, & Earnings